Kiora Pharmaceuticals Inc KPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.49
- Day Range
- $0.49–0.52
- 52-Week Range
- $0.45–2.65
- Bid/Ask
- $0.49 / $0.50
- Market Cap
- $12.77 Mil
- Volume/Avg
- 228,687 / 244,810
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://www.kiorapharma.com
Valuation
|
Metric
|
KPRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.61 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
KPRX
Financial Strength
|
Metric
|
KPRX
|
|---|---|
Quick Ratio | 2.76 |
Current Ratio | 2.90 |
Interest Coverage | −1,130.65 |
Quick Ratio
KPRX
Profitability
|
Metric
|
KPRX
|
|---|---|
Return on Assets (Normalized) | −43.42% |
Return on Equity (Normalized) | −74.41% |
Return on Invested Capital (Normalized) | −75.19% |
Return on Assets
KPRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wjcspnfmq | Lyk | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xqphbhcb | Gxcdmn | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qlsmychb | Jgmmrn | $105.3 Bil | |
MRNA
| Moderna Inc | Hxfglmzfc | Wzc | $47.0 Bil | |
ARGX
| argenx SE ADR | Lnmsjqtb | Plvj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ptpkcgcp | Gxns | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ykpgfxnrr | Xfqczf | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bnbkgwvy | Ygzmjy | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yxjblpxplm | Ldyxlz | $12.7 Bil | |
INCY
| Incyte Corp | Pqqrvwqk | Jgnsj | $12.0 Bil |